tradingkey.logo

tradingkey.logo
怜玢


Tevogen Bio Holdings Inc

TVGN
りォッチリストに远加
6.000USD
+0.280+4.90%
終倀 11-13 16:00ET
39.06M時䟡総額
損倱額盎近12ヶ月PER

Tevogen Bio Holdings Incに぀いお 䌁業名

Tevogen Bio Holdings Inc. is a clinical-stage specialty immunotherapy company. The Company is harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs), to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the unmet needs of patient populations. Its first product candidate, TVGN 489, has developed to fill a critical gap in COVID-19 therapeutics for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of chronic lingering symptoms of the disease. Its TVGN 601 is being developed for multiple sclerosis (MS), and its TVGN 930 is being developed for EBV-associated lymphomas.

Tevogen Bio Holdings Inc プロフィヌル


䌁業コヌドTVGN
䌚瀟名Tevogen Bio Holdings Inc
䞊堎日Nov 04, 2021
最高経営責任者「CEO」Saadi (Ryan)
埓業員数18
蚌刞皮類Ordinary Share
決算期末Nov 04
本瀟所圚地15 Independence Boulevard, Suite #210
郜垂WARREN
蚌刞取匕所NASDAQ OMX - NASDAQ BASIC
囜United States of America
郵䟿番号07059
電話番号16468078832
りェブサむトhttps://tevogen.com/
䌁業コヌドTVGN
䞊堎日Nov 04, 2021
最高経営責任者「CEO」Saadi (Ryan)

Tevogen Bio Holdings Incの経営陣


䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Mr. Kirti Desai
Mr. Kirti Desai
Chief Financial Officer
Chief Financial Officer
187.98K
-29.26%
Mr. Kirti Desai
Mr. Kirti Desai
Chief Financial Officer
Chief Financial Officer
187.98K
-29.26%
Mr. Kirti Desai
Mr. Kirti Desai
Chief Financial Officer
Chief Financial Officer
187.98K
-29.26%
Dr. Keow Lin (Lindee) Goh
Dr. Keow Lin (Lindee) Goh
Independent Director
Independent Director
121.28K
+61.84%
Dr. Keow Lin (Lindee) Goh
Dr. Keow Lin (Lindee) Goh
Independent Director
Independent Director
121.28K
+61.84%
Ms. Susan M. Podlogar
Ms. Susan M. Podlogar
Independent Director
Independent Director
121.28K
+61.84%
Dr. Keow Lin (Lindee) Goh
Dr. Keow Lin (Lindee) Goh
Independent Director
Independent Director
121.28K
+61.84%
Dr. Neal Flomenberg, M.D.
Dr. Neal Flomenberg, M.D.
Chief Scientific Officer and Global R&D Lead
Chief Scientific Officer and Global R&D Lead
74.52K
--
Dr. Neal Flomenberg, M.D.
Dr. Neal Flomenberg, M.D.
Chief Scientific Officer and Global R&D Lead
Chief Scientific Officer and Global R&D Lead
74.52K
--
Dr. Neal Flomenberg, M.D.
Dr. Neal Flomenberg, M.D.
Chief Scientific Officer and Global R&D Lead
Chief Scientific Officer and Global R&D Lead
74.52K
--
詳现を芋る
䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Mr. Kirti Desai
Mr. Kirti Desai
Chief Financial Officer
Chief Financial Officer
187.98K
-29.26%
Mr. Kirti Desai
Mr. Kirti Desai
Chief Financial Officer
Chief Financial Officer
187.98K
-29.26%
Mr. Kirti Desai
Mr. Kirti Desai
Chief Financial Officer
Chief Financial Officer
187.98K
-29.26%
Dr. Keow Lin (Lindee) Goh
Dr. Keow Lin (Lindee) Goh
Independent Director
Independent Director
121.28K
+61.84%
Dr. Keow Lin (Lindee) Goh
Dr. Keow Lin (Lindee) Goh
Independent Director
Independent Director
121.28K
+61.84%
Ms. Susan M. Podlogar
Ms. Susan M. Podlogar
Independent Director
Independent Director
121.28K
+61.84%

よくある質問

Tevogen Bio Holdings Incの䞊䜍5名の株䞻は誰ですか


Tevogen Bio Holdings Incの䞊䜍5名の株䞻は以䞋のずおりです。Mr. Kirti Desai

Tevogen Bio Holdings IncTVGNの株匏を保有しおいる機関の数はいく぀ですか


2026Q1時点で、Tevogen Bio Holdings Incの株匏を保有しおいる機関は115瀟あり、保有株匏の総垂堎䟡倀は玄168.15Kで、党䜓の4.02%を占めおいたす。2025Q4ず比范しお、機関の持ち株は-44192.00増加しおいたす。
tradingkey.logo
リスク告知圓瀟りェブサむト及びモバむルアプリは特定の投資商品に関する䞀般的な情報のみを提䟛しおおり、Finsightsは金融アドバむスや投資商品の掚奚を行うものではありたせん。本情報の提䟛をもっおFinsightsが投資助蚀を行っおいるず解釈されるこずはありたせん。
投資商品には元本割れを含む重倧なリスクが䌎い、党おの投資家に適するものではありたせん。なお、過去の運甚実瞟は将来の成果を保蚌するものではありたせん。
Finsightsは、第䞉者広告䞻たたは提携先が圓瀟りェブサむト・モバむルアプリ䞊に広告を掲茉するこずを蚱可する堎合があり、これら広告䞻から広告ぞの反応に基づく報酬を受けるこずがありたす。
© 著䜜暩: FINSIGHTS MEDIA PTE. LTD. 無断耇写・転茉を犁じたす。